Quick Answer
RxSight, Inc. reported Stockholders Equity of $275.68 million for the year ending 2025.
- RxSight, Inc. showed a decrease of -2.0% in Stockholders Equity from 2024 to 2025.
- This data is from RxSight, Inc.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: -$313.40 million | Q3 2021: $150.89 million | Q1 2022: $123.16 million | Q2 2022: $109.99 million | Q3 2022: $95.96 million | Q1 2023: $145.01 million | Q2 2023: $157.19 million | Q3 2023: $161.48 million | Q1 2024: $163.93 million | Q2 2024: $275.21 million | Q3 2024: $277.26 million | Q1 2025: $279.32 million | Q2 2025: $278.01 million | Q3 2025: $275.97 million.
- Over the full 6 years of available data (2020 to 2025), RxSight, Inc.'s Stockholders Equity has grown by 164.0%.
- Historical annual values: Fiscal year 2025: $275.68 million | Fiscal year 2024: $281.24 million | Fiscal year 2023: $160.36 million | Fiscal year 2022: $89.90 million | Fiscal year 2021: $138.24 million | Fiscal year 2020: -$430.59 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: